Latest News and Press Releases
Want to stay updated on the latest news?
-
MELBOURNE, Australia, Jan. 31, 2023 (GLOBE NEWSWIRE) -- MRHB, the world’s first halal decentralized finance (DeFi) ecosystem, has recently bagged two awards from Singapore-based World Business...
-
~Patients And Doctors Celebrated in Emotion-Packed Performance~JULIE BOWEN, GARY COLE, JON HUERTAS plus more…CHRISTOPHER GORHAM, “THE LINCOLN LAWYER,” emceeJonnie Davis, President of ABC Signature...
-
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
-
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019 --RedHill and Daiichi Sankyo replaced their co-commercialization...
-
RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
-
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
-
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC ...
-
BETHESDA, Md., June 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today issued the following statement regarding the...
-
BETHESDA, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, "A Randomized Study of...
-
BETHESDA, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...